Please login to the form below

Not currently logged in
Email:
Password:

Abbott to pay $1.67bn to J&J

A US federal jury has ruled that Abbott is to pay Johnson & Johnson $1.67bn for infringing a patent

A US federal jury has ruled that Abbott is to pay Johnson & Johnson (J&J)  $1.67bn for infringing a patent that was allegedly used to develop its arthritis drug Humira (adalimumab).

The Texan court determined that Abbott's actions were willful and sided with J&J, the world's biggest healthcare company. J&J is owed $1.17bn in lost profits and $504m in royalties. Abbott has said it will appeal the verdict.

Abbott spokesperson Scott Stoffel remarked: "We are confident in the merits of our case and that we will prevail on appeal."

Centocor claimed that Humira is made using technology developed by New York University (NYU) and exclusively licensed to the J&J unit. The NYU property related to antibodies against tumour necrosis factor (TNF), which is linked to inflammation. Humira works by blocking the action of the TNF protein.

Humira generated $4.5bn in global sales last year, around 15 per cent of Abbotts' total revenue. The company has projected global sales of 15 to 20 per cent this year.

Kim Taylor, President of J&J's Centocor Ortho Biotech unit, said: "We are particularly gratified that the jury recognised our valuable intellectual property, finding our patent both valid and infringed."

30th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics